Jerusalem, 18 December, 2025 (TPS-IL) — Israeli biopharmaceutical company Protalix BioTherapeutics has signed a collaboration and option agreement with Germany’s Secarna Pharmaceuticals to jointly develop antisense oligonucleotide therapies for rare kidney diseases. Under the deal, Protalix will select biological targets, while Secarna will use its AI-powered OligoCreator platform to design and profile drug candidates. The partners aim to advance selected programs from preclinical research toward clinical trials.
Protalix has received an option to acquire an exclusive, worldwide license to further develop, commercialize and market any resulting compounds, with milestone and royalty payments to Secarna. The agreement marks Protalix’s expansion into RNA-based therapies for rare renal conditions.